2509 Stock Overview
A clinical-stage biotech company, focuses on the research and development of biologic therapies for autoimmune and allergic diseases in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Qyuns Therapeutics Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$6.92 |
| 52 Week High | HK$30.95 |
| 52 Week Low | HK$5.95 |
| Beta | 0 |
| 1 Month Change | 3.13% |
| 3 Month Change | -18.87% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -71.76% |
Recent News & Updates
Shareholder Returns
| 2509 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 3.3% | 2.2% | 4.3% |
| 1Y | n/a | 13.2% | 28.1% |
Return vs Industry: Insufficient data to determine how 2509 performed against the Hong Kong Biotechs industry.
Return vs Market: Insufficient data to determine how 2509 performed against the Hong Kong Market.
Price Volatility
| 2509 volatility | |
|---|---|
| 2509 Average Weekly Movement | 17.0% |
| Biotechs Industry Average Movement | 7.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in HK Market | 13.8% |
| 10% least volatile stocks in HK Market | 3.0% |
Stable Share Price: 2509's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2509's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 325 | n/a | www.qyuns.net |
Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, focuses on the research and development of biologic therapies for autoimmune and allergic diseases in the People’s Republic of China. The company’s lead product candidates include QX002N, an interleukin (IL)-17A inhibitor in Phase III clinical trial for the treatment of ankylosing spondylitis and lupus nephritis; and QX005N, a monoclonal antibody (mAb) blocking IL-4Ra, which has completed Phase II clinical trial, to treat atopic dermatitis, prurigo nodularis, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria (CSU), asthma, and chronic obstructive pulmonary disease (COPD). It also develops QX001S, an IL-12/IL-23p40 inhibitor in Phase III clinical trial for the treatment of psoriasis (Ps), and ulcerative colitis/Crohn’s disease (CD); QX004N an IL-23p19 inhibitor in Phase II clinical trial to treat Ps and CD; QX006N, an IFNAR1-targeting mAb, which is in Phase Ib clinical trial, for the treatment of systemic lupus erythematosus; and QX008N, a humanized IgG1 mAb targeting thymic stromal lymphopoietin in Phase Ib clinical trial to treat moderate-to-severe asthma and COPD.
Qyuns Therapeutics Co., Ltd. Fundamentals Summary
| 2509 fundamental statistics | |
|---|---|
| Market cap | HK$1.54b |
| Earnings (TTM) | -HK$452.53m |
| Revenue (TTM) | HK$64.02m |
24.0x
P/S Ratio-3.4x
P/E RatioIs 2509 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2509 income statement (TTM) | |
|---|---|
| Revenue | CN¥59.67m |
| Cost of Revenue | CN¥7.16m |
| Gross Profit | CN¥52.51m |
| Other Expenses | CN¥474.31m |
| Earnings | -CN¥421.80m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.90 |
| Gross Margin | 88.00% |
| Net Profit Margin | -706.89% |
| Debt/Equity Ratio | 137.5% |
How did 2509 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 06:12 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Qyuns Therapeutics Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.